Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (121-130 of 436) with videos related to

Pageof 44
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal DysfunctionKoji Sasaki, Amit Lahoti, Elias Jabbour, et al.
Blood Advances|October 28, 2020
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitorsHelen T Chifotides, Lucia Masarova, Mansour Alfayez, et al.
Leukemia Research|July 18, 2015
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phaseTalha Badar, Hagop M Kantarjian, Farhad Ravandi, et al.
The Lancet. Haematology|May 31, 2025
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trialMika Kontro, Anthony Selwyn Stein, Marja Pyörälä, et al.
American Journal of Hematology|March 4, 2015
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemiaJuan Ouyang, Maitrayee Goswami, Guilin Tang, et al.
Frontiers in Oncology|April 26, 2021
IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaClaudio Cerchione, Alessandra Romano, Naval Daver, et al.
Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|January 9, 2019
Leukemic Involvement in the ThoraxGirish S Shroff, Mylene T Truong, Brett W Carter, et al.
British Journal of Haematology|February 27, 2015
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemiaTapan Kadia, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
American Journal of Hematology|January 25, 2014
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromesNaval Daver, Kiran Naqvi, Elias Jabbour, et al.
Pageof 44

Showing results (121-130 of 436) with videos related to

Sort By:
Pageof 44
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal DysfunctionKoji Sasaki, Amit Lahoti, Elias Jabbour, et al.
Blood Advances|October 28, 2020
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitorsHelen T Chifotides, Lucia Masarova, Mansour Alfayez, et al.
Leukemia Research|July 18, 2015
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phaseTalha Badar, Hagop M Kantarjian, Farhad Ravandi, et al.
The Lancet. Haematology|May 31, 2025
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trialMika Kontro, Anthony Selwyn Stein, Marja Pyörälä, et al.
American Journal of Hematology|March 4, 2015
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemiaJuan Ouyang, Maitrayee Goswami, Guilin Tang, et al.
Frontiers in Oncology|April 26, 2021
IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaClaudio Cerchione, Alessandra Romano, Naval Daver, et al.
Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|January 9, 2019
Leukemic Involvement in the ThoraxGirish S Shroff, Mylene T Truong, Brett W Carter, et al.
British Journal of Haematology|February 27, 2015
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemiaTapan Kadia, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
American Journal of Hematology|January 25, 2014
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromesNaval Daver, Kiran Naqvi, Elias Jabbour, et al.
Pageof 44